iCAD, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- iCAD, Inc. (NASDAQ: ICAD) develops and markets AI-powered solutions for cancer detection and risk assessment, primarily focused on breast health applications including detection, density assessment, and personalized risk evaluation. The company offers the ProFound Breast Health Suite, which provides clinically proven tools for breast cancer screening on 2D and 3D mammography; solutions for breast density scoring to inform treatment plans; one- and two-year breast cancer risk models that outperform traditional methods; and cardiovascular risk assessment via breast arterial calcification analysis; as well as image analysis workflow tools for digital breast tomosynthesis, full-field digital mammography, MRI, and CT to identify pathologies earlier. Founded in 1984 and headquartered in Nashua, New Hampshire, iCAD serves radiologists, healthcare providers, and patients globally in over 50 countries through direct sales, OEM partners, distributors, and resellers, with FDA clearance, CE marking, and Health Canada licensing for key products. In July 2025, RadNet Inc.'s wholly-owned subsidiary DeepHealth completed the acquisition of iCAD in an all-stock transaction, integrating its AI portfolio into DeepHealth's offerings to accelerate breast cancer screening, enhance workflow efficiency, and expand access across RadNet's network of imaging centers; recent strategic moves also include partnerships with Microsoft for Precision Imaging Network integration, RamSoft for North American distribution of ProFound AI mammography solutions, and Koios Medical for multi-modality breast cancer detection; alongside executive appointments such as Mark Koeniguer as Chief Commercial Officer in April 2025.
ICAD INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of iCAD, Inc. - ICAD
iCAD Reports Financial Results for First Quarter Ended March 31, 2025
ICAD INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of iCAD, Inc. - ICAD
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of iCAD, Inc. - ICAD
ICAD Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of iCad, Inc. Is Fair to Shareholders
iCAD Expands Executive Leadership with Appointment of Mark Koeniguer as Chief Commercial Officer
iCAD, Inc. (ICAD) Q4 2024 Earnings Call Transcript
iCAD Reports Financial Results for Fourth Quarter and Fiscal Year Ended December 31, 2024
iCAD and RamSoft Announce Partnership to Deliver ProFound® AI-Powered Mammography Solutions Across North America
Koios Medical and iCAD Partner to Expand AI-Powered, Multi-Modality Breast Cancer Detection Solutions at ECR 2025
iCAD To Showcase Five AI-Powered Research Presentations Advancing Breast Cancer Detection, Risk Evaluation, and Breast Arterial Calcification Assessment at ECR 2025
iCAD Pre-Announces Estimated Q4 2024 Revenue
Izotropic Announces Team Leading Clinical Study Design and FDA Regulatory Submissions
SABCS 2024: New Research Assesses iCAD's Image Based AI-Risk, Detection, and Breast Arterial Calcifications (BAC) Assessment Across Diverse Populations
CORRECTION – iCAD Advances Fight Against Breast Cancer with FDA-cleared, Next-Generation AI Solutions and ProFound Health Partnership with Cascaid Health at RSNA 2024
iCAD Advances Fight Against Breast Cancer with FDA-cleared, Next-Generation AI Solutions and a Second-Read AI Partnership with Cascaid Health at RSNA 2024
iCAD, Inc. (ICAD) Q3 2024 Earnings Call Transcript
iCAD Reports Financial Results for Third Quarter Ended September 30, 2024
iCAD to Attend 15th Annual Craig-Hallum Alpha Select Conference
iCAD to Participate in the LD Micro Main Event XVII